Baxter International Inc
NYSE: BAX · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
Updated 2026-05-11
Baxter International Inc (BAX) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for BAX.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
BAX historical valuation range
Where current P/E sits in BAX's own 5Y range.
BAX intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
BAX valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 0.80x
Is BAX overvalued in 2026?
Baxter International Inc (BAX) currently trades at $17.53 per share with a market capitalization of $9,053,702,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 51/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
BAX currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 0.8x, the market is valuing the company primarily on its revenue rather than its earnings.
Looking at its own history, BAX is currently trading cheaper than 100% of the last 5Y on P/E. This places it in the 0th percentile of its historical range, a level that has historically coincided with attractive entry points.
Our discounted cash flow model estimates BAX's intrinsic value at $60.34 per share, against the current market price of $17.53. This implies a margin of safety of +63.09%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: BAX trades at a fair valuation on our framework, with a Smart Value Score of 51/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is BAX overvalued in 2026?
Based on a Smart Value Score of 51/100, BAX is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is BAX's fair value?
Our DCF model estimates BAX's intrinsic value at $60.34 per share, versus the current price of $17.53. This produces a margin of safety of +63.09%.
What P/E ratio does BAX trade at?
BAX does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.
Is BAX a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 51/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does BAX's valuation compare to its history?
On P/E, BAX currently sits in the 0th percentile of its own 5Y range. That is historically cheap relative to where it has traded over the period.
What is BAX's Smart Value Score?
BAX's Smart Value Score is 51/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.